Skip to Content

Keveyis (dichlorphenamide) Disease Interactions

There are 9 disease interactions with Keveyis (dichlorphenamide):

Major

Dichlorphenamide (Includes Keveyis) ↔ Acidosis

Severe Potential Hazard, Moderate plausibility

Applies to: Acidosis

The use of dichlorphenamide is contraindicated acidotic patients (hyperchloremic or respiratory).

Major

Dichlorphenamide (Includes Keveyis) ↔ Adrenocortical Insufficiency

Severe Potential Hazard, Moderate plausibility

Applies to: Adrenal Insufficiency

The use of dichlorphenamide is contraindicated in adrenocortical insufficiency.

Major

Dichlorphenamide (Includes Keveyis) ↔ Dehydration

Severe Potential Hazard, Moderate plausibility

Applies to: Dehydration, Hypokalemia, Hyponatremia

The use of dichlorphenamide is contraindicated in patients with hyponatremia or hypokalemia, or in conditions in which serum levels of sodium or potassium are depressed.

Major

Dichlorphenamide (Includes Keveyis) ↔ Hepatic Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of dichlorphenamide is contraindicated in hepatic insufficiency.

Major

Dichlorphenamide (Includes Keveyis) ↔ Pulmonary Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Chronic Obstructive Pulmonary Disease

Dichlorphenamide should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation as their acidosis may be increased.

Major

Dichlorphenamide (Includes Keveyis) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of dichlorphenamide is contraindicated in renal failure.

Moderate

Carbonic Anhydr. Inhibitors (Includes Keveyis) ↔ Respiratory Acidosis

Moderate Potential Hazard, Low plausibility

Applies to: Acidosis, Chronic Obstructive Pulmonary Disease

Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels. Respiratory acidosis may be precipitated or increased in these patients. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis. Respiratory status should be monitored during therapy.

References

  1. Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979): 284-6
  2. "Product Information. Diamox (acetazolamide)." Lederle Laboratories, Wayne, NJ.
  3. Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 (1984-85): 549-63
Moderate

Carbonic Anhydrase Inhibitors (Includes Keveyis) ↔ Diabetes Mellitus

Moderate Potential Hazard, Low plausibility

Applies to: Diabetes Mellitus

Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus. Routine glucose monitoring is recommended during therapy.

References

  1. Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979): 284-6
  2. "Product Information. Diamox (acetazolamide)." Lederle Laboratories, Wayne, NJ.
  3. Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991): 457-64
Moderate

Carbonic Anhydrase Inhibitors (Includes Keveyis) ↔ Gout

Moderate Potential Hazard, Moderate plausibility

Applies to: Gout

Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout. Elevated serum uric acid levels return to normal when the drug is discontinued. Monitoring of uric acid levels is recommended in these patients.

References

  1. "Product Information. Diamox (acetazolamide)." Lederle Laboratories, Wayne, NJ.
  2. Ferry AP, Lichtig M "Gouty arthritis as a complication of acetazolamide (diamox) therapy for glaucoma." Can J Ophthalmol 4 (1969): 145-7

Keveyis (dichlorphenamide) drug Interactions

There are 371 drug interactions with Keveyis (dichlorphenamide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide